Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021

OSLO, Norway, April 1, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial with Betalutin® in advanced follicular lymphoma (FL) as well as to extend its cash runway into 2021. A...

from PR Newswire: https://ift.tt/2wIwj0Z